Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Other solid neoplasm 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Mesothelioma 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Adrenocortical Carcinoma 1

Interventions

Injections 17Cisplatin 15Carboplatin 15Oxaliplatin 11Gemcitabine 11pembrolizumab 8Capecitabine 8toripalimab 7Paclitaxel 7Etoposide 7Cyclophosphamide 7Pemetrexed 6Irinotecan 6Drug Therapy 6spartalizumab 5fludarabine 5camrelizumab 5Vincristine 5Radiotherapy 5Leucovorin 5tislelizumab 4apatinib 4anlotinib 4Interleukin-2 4Immune Checkpoint Inhibitors 4Granulocyte-Macrophage Colony-Stimulating Factor 4Fluorouracil 4Docetaxel 4Bevacizumab 4tremelimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × IPI-549 × Other solid neoplasm × Clear all
NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Infinity Pharmaceuticals, Inc.

Phase 1 Unknown
219 enrolled
BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡